Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.54 |
| ▸ | PLAU | P00749 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 3/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
| ▸ | ANPEP | P15144 | 1/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | PREP | P48147 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6406079 | 0.84 | IDO1 (0.47) | CYP19A1PLAUSIGMAR1 | |
| SCHEMBL6427595 | 0.79 | CYP19A1 (0.54) | CYP19A1PLAUHTR1ASIGMAR1OPRM1 | |
| SCHEMBL6570371 | 0.79 | CYP19A1 (0.54) | CYP19A1PLAUHTR1ASIGMAR1OPRM1 | |
| SCHEMBL27278343 | 0.79 | CYP19A1 (0.54) | CYP19A1PLAUHTR1ASIGMAR1OPRM1 | |
| SCHEMBL15701675 | 0.79 | CYP19A1 (0.54) | CYP19A1PLAUHTR1ASIGMAR1OPRM1 | |
| SCHEMBL6427588 | 0.79 | CYP19A1 (0.54) | CYP19A1PLAUHTR1ASIGMAR1OPRM1 | |
| SCHEMBL9935276 | 0.79 | CYP19A1 (0.54) | CYP19A1PLAUHTR1ASIGMAR1OPRM1 | |
| SCHEMBL1689733 | 0.79 | PLAU (0.55) | CYP19A1PLAUHTR1ASIGMAR1OPRM1 | |
| SCHEMBL6428907 | 0.79 | CYP19A1 (0.54) | CYP19A1PLAUHTR1ASIGMAR1OPRM1 | |
| SCHEMBL599314 | 0.79 | CYP19A1 (0.54) | CYP19A1PLAUHTR1ASIGMAR1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150158842-A1 | PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-06-11 | — | — | US | disclosed |
| US-9045459-B2 | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-06-02 | — | — | US | disclosed |
| US-20120088790-A1 | PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2012-04-12 | — | — | US | disclosed |
| US-6602888-B2 | Binds to a human alpha 1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human alpha 1A adrenergic receptor | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-08-05 | — | — | US | disclosed |
| US-20030022900-A1 | Compositions comprising alpha-1C specific compounds | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-01-30 | — | — | US | disclosed |
| US-20020032219-A1 | USE OF ALPHA-1C SPECIFIC COMPOUNDS TO TREAT BENIGN PROSTATIC HYPERPLASIA | H. LUNDBECK A/S (DK) | 2002-03-14 | — | — | US | disclosed |
| US-6015819-A | ADMINISTERING ADRENERGIC BLOCKING AGENT; REDUCTION OF ORTHOSTATIC FALL IN BLOOD PRESSURE SIDE EFFECT; FDA ORANGE BOOK LISTED PATENT FOR SILODOSIN | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-01-18 | — | — | US | disclosed |
| US-5990128-A | ADMINISTERING AN ANTAGONIST THAT BINDS TO A HUMAN ALPHA-1C ADRENERGIC RECEPTOR WITH A BINDING AFFINITY AT LEAST 691-FOLD HIGHER THAN THE BINDING AFFINITY WITH WHICH THE ANTAGONIST BINDS TO A HUMAN ALPHA-1B ADRENERGIC RECEPTOR | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1999-11-23 | — | — | US | disclosed |
| EP-0758894-A4 | USE OF ALPHA-1C SPECIFIC COMPOUNDS TO TREAT BENIGN PROSTATIC HYPERPLASIA | SYNAPTIC PHARMA CORP (US) | 1999-05-19 | — | — | EP | disclosed |
| US-5780485-A | ADMINISTERING ADRENERGIC BLOCKING AGENT; SIDE EFFECT REDUCTION; FDA ORANGE BOOK LISTED PATENT FOR SILODOSIN | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1998-07-14 | — | — | US | disclosed |
| EP-0667769-A4 | USE OF ALPHA-1C SPECIFIC COMPOUNDS TO TREAT BENIGN PROSTATIC HYPERPLASIA. | SYNAPTIC PHARMA CORP (US) | 1998-02-04 | — | — | EP | disclosed |
| EP-0758894-A1 | USE OF ALPHA-1C SPECIFIC COMPOUNDS TO TREAT BENIGN PROSTATIC HYPERPLASIA | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1997-02-26 | — | — | EP | disclosed |
| US-5578611-A | ANTITUMOR AGENTS AND PROSTATE TUMOR DETECTION BY BINDING HUMAN ALPHA-ADRENERGIC RECEPTOR AND HISTAMINE H1 RECEPTORS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1996-11-26 | — | — | US | disclosed |
| US-5508306-A | USED FOR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA, LOWERING INTRAOCULAR PRESSURE AND INHIBITING CHOLESTEROL SYNTHESIS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1996-04-16 | — | — | US | disclosed |
| WO-1995028157-A1 | USE OF ALPHA-1C SPECIFIC COMPOUNDS TO TREAT BENIGN PROSTATIC HYPERPLASIA | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1995-10-26 | — | — | WO | disclosed |
| EP-0667769-A1 | USE OF ALPHA-1C SPECIFIC COMPOUNDS TO TREAT BENIGN PROSTATIC HYPERPLASIA | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1995-08-23 | — | — | EP | disclosed |
| US-5403847-A | Administering a therapeutic amount of a compound which binds to a human alpha 1c adrenergic receptor; FDA Orange book listed patent for silodosin | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1995-04-04 | — | — | US | disclosed |
| WO-1994010989-A1 | USE OF ALPHA-1C SPECIFIC COMPOUNDS TO TREAT BENIGN PROSTATIC HYPERPLASIA | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1994-05-26 | — | — | WO | disclosed |
| US-4705871-A | Aralkoxy and aryloxyalkoxy kojic acid derivatives | G. D. SEARLE & CO. (US) | 1987-11-10 | — | — | US | disclosed |
| US-4644071-A | Aralkoxy and aryloxyalkoxy kojic acid derivatives | G. D. SEARLE & CO. (US) | 1987-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022900-A1 | Compositions comprising alpha-1C specific compounds | ADRB1, ADRA1B, ADRA1A | CYP19A1 604/4885PLAU 3204/4885HTR1A 26/4885 |
| US-20150158842-A1 | PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | KCNT1, CEPT1, PIGT | CYP19A1 3570/4885PLAU 2342/4885HTR1A 478/4885 |
| US-20020032219-A1 | USE OF ALPHA-1C SPECIFIC COMPOUNDS TO TREAT BENIGN PROSTATIC HYPERPLASIA | ADRB1, ADRA1B, ADRA1A | CYP19A1 670/4885PLAU 2412/4885HTR1A 21/4885 |
| US-20120088790-A1 | PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | KCNT1, CEPT1, PIGT | CYP19A1 3570/4885PLAU 2342/4885HTR1A 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.